The TRIFic™ exosome detection assay from Cell Guidance Systems is a reliable method for the detection and quantification of exomes from purified or unpurified samples. Using a highly sensitive europium label, the TRIFic exosome assays are ideal for the rapid and sensitive detection of CD9, CD81 and CD63 directly in blood, plasma, cell culture media, urine and other biological fluid samples.
Benefits of using the TRIFic Exosome Assay
• Only antigens displayed in multiple copies are detected
• High reproducibility
• Highly sensitive europium label
• Compatible with purified and unpurified samples
• CD9, CD63 & CD81 assays available
TRIFic protocol overview
Step 1: Biotinylated antibody is bound to the streptavidin-coated assay plate.
Step 2: Biological samples containing exosomes are added to the plate. Exosomes bearing the appropriate antigen (CD9, CD63, or CD81) and any free antigen are captured by the immobilised antibody.
Step 3: Europium-labelled antibody is added and binds specifically to exosome antigens. Free antigen is not bound by the europium-labelled antibody (since the epitope is already occupied by the immobilised antibody) and is therefore not detected. Samples are read in a time-resolved fluorescence plate reader.
TRIFic exosome detection assay scientific data on unpurified samples
CD9 TRIFic exosome assay performed for a variety of cell lines (n=2). Over 80 samples plus exosome controls can be tested with a single kit.
TRIFic exosome analysis
TRIFic exosome analysis of CD9 in 20 cancer patient urine samples demonstrating a wide range of exosomal content.